IP Strategy for Drug Discovery: A Dedicated Research Firm’s Perspective

By Vinita Radhakrishnan Given the nature of business of a dedicated research firm (DRF) in the pharmaceutical sector, intellectual property (IP), particularly, patents are considered to be the most valued asset. More times than not, the standing of a dedicated research firm, in the market place, is judged by the strength and nature of their […]

The Glassybaby Syndrome or Why Every Company is an IP Company

By Louis Carbonneau Ever heard of Glassybaby? According to a recent Seattle Times article, “[Glassybaby] is a compelling small-business success story: After a seven-year battle with lung cancer, young mother develops colorful and inspirational product, hires local artisans, donates 10 percent of sales to charity and sells 20 percent stake to billionaire Jeff Bezos.” For […]

Life sciences IP management in an age of opportunity

By Peter A Ackerman and Russell L Parr The life sciences industries provide some of the best examples of the risk/reward continuum inherent in the creation and commercialisation of ideas. The risks are considerable given the costs of complex research and development, regulatory requirement, and intellectual property owned by others that must be manoeuvred in order […]

Getting the most from your IP agent networks

By Donal O’Connell IP agent networks stretch around the globe and through every industry sector. Donal O’Connell and Sabine Baum outline best practice for managing those networks and turning them into crucial business assets One of the most essential elements in supporting a global intellectual property (IP) portfolio is the network of IP agents and […]

IP Strategy for Startups

By Ian Maxwell Here are two very true statements A startup should have a patent portfolio Startups can rarely afford to properly invest in a patent portfolio With this fundamental paradox in mind, this article describes some of the options that startups have with respect to IP strategies that most effectively balance the costs and […]

IP diligence is a constant

By Peter Ackerman What do a Koosh ball and a tab of Viagra have in common? Aside from the pleasure they bring to millions, their economic success is premised upon the same type of IP protection. The company that makes Koosh balls – rainbow-coloured, plasma-filled rubber balls with protruding soft rubber spikes – and the […]

What is IP Strategy?

By Ralph Eckardt “Over the last 10 years, it has become imperative for CEOs to have not just a general understanding of the intellectual property issues facing their business and their industry, but to have quite a refined expertise relating to those issues… It is no longer simply the legal department’s problem. CEOs must now […]

Brand Licensing in Emerging Markets – Top 10 Mistakes

By Ben Goodger Mistake 1. Don’t take account of the local market The classic and most frequent mistake is to assume that a formula for the licensing or franchising of a brand in one market will work equally well, unamended and unadapted, in another market. This is well illustrated by the story of KFC in […]

Low R&D Cost Per-Patent is a Poor Indicator of Good Return

By Bruce Berman Patent Yield-Per-R&D Dollar Varies Widely by Industry, Technology & Business Model For most businesses obtaining patents and costly R&D go together like love and marriage – you can’t have one with out the other. Or can you? The cost of R&D that underlies a particular invention varies greatly by industry, business model […]

Eight Species of Patent Strategy – Part 3 how intellectual property management develops from level 3 to level 4

By Bill Meade Intellectual Property Management in a Growing Soon-To-Be-Company: Once a growing company signs its first cross license with a balancing payment going out, or has a “near death experience” with IP litigation, and/or loses a patent litigation, IP management gains its first proposition with senior management.  The value of IP becomes intuitively obvious […]